- Article
- Source: Campus Sanofi
- 23 Oct 2023
AUBAGIO® (teriflunomide) Overview: Efficacy (Brain Health) and Real-World (Patient-Reported Outcomes, Adherence, Effectiveness) - Prof. Jiwon Oh
Prescribing Information can be found through the links at the Product Carousel on the bottom of the page.
Speaker:
Professor Jiwon Oh, MD, PhD
St. Michael’s Hospital, University of Toronto, Canada
Learning Objectives:
-
To understand the role AUBAGIO® can play in helping to protect brain function
-
To understand that neurodegeneration and brain atrophy are associated with disease progression, independent of acute focal activity
-
To recognise that real-world efficacy and safety trials of AUBAGIO® supports clinical outcomes
Reflective learning guide and CPD certificate
Related Videos
22:30
AUBAGIO® (teriflunomide): MoA and Safety - Prof. Patrick Vermersch
18:56
Preserving Brain Health | Part 1: Underlying Pathology of Chronic Smouldering MS - Prof. Gavin Giovannoni
19:17
Preserving Brain Health | Part 2: Clinical Progression and Smouldering Disease - Prof. Gavin Giovannoni
24:53
Preserving Brain Health | Part 3: Advanced Imaging Techniques in Routine Clinical Practice - Prof. Jiwon Oh
22:30
AUBAGIO® (teriflunomide): MoA and Safety - Prof. Patrick Vermersch
18:56
Preserving Brain Health | Part 1: Underlying Pathology of Chronic Smouldering MS - Prof. Gavin Giovannoni
19:17
Preserving Brain Health | Part 2: Clinical Progression and Smouldering Disease - Prof. Gavin Giovannoni
24:53
Preserving Brain Health | Part 3: Advanced Imaging Techniques in Routine Clinical Practice - Prof. Jiwon Oh
Neurology Products
%20-%20Copy%20(1).png){kind=logo}
|
Prescribing Information GB MAT-XU-2200676 (v6.0) |
%20(1).png){kind=logo}
|
Prescribing Information GB MAT-XU-2200680 (v3.0) |
MAT-XU-2201535 (v5.0) Date of preparation: October 2023